메뉴 건너뛰기




Volumn 15, Issue 6, 2014, Pages 470-474

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: A case series

Author keywords

Crizotinib; FISH; IHC; NSCLC; ROS1

Indexed keywords

CARBOPLATIN; CISPLATIN; CRIZOTINIB; ONCOPROTEIN; PEMETREXED; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

EID: 84908200713     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.06.004     Document Type: Article
Times cited : (14)

References (6)
  • 1
    • 36849065315 scopus 로고    scopus 로고
    • Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
    • K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
    • (2007) Cell , vol.131 , pp. 1190-1203
    • Rikova, K.1    Guo, A.2    Zeng, Q.3
  • 2
    • 84865089246 scopus 로고    scopus 로고
    • Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion
    • V. Rimkunas, K.E. Crosby, and D. Li Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion Clin Cancer Res 18 2012 4449 4457
    • (2012) Clin Cancer Res , vol.18 , pp. 4449-4457
    • Rimkunas, V.1    Crosby, K.E.2    Li, D.3
  • 3
    • 84863338079 scopus 로고    scopus 로고
    • ROS1 rearrangements define a unique molecular class of lung cancers
    • K. Bergethon, A.T. Shaw, and S.H. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
    • (2012) J Clin Oncol , vol.30 , pp. 863-870
    • Bergethon, K.1    Shaw, A.T.2    Ou, S.H.3
  • 4
    • 80052969848 scopus 로고    scopus 로고
    • MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations
    • J. Tanizaki, I. Okamoto, and K. Okamoto MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations J Thorac Oncol 6 2011 1624 1631
    • (2011) J Thorac Oncol , vol.6 , pp. 1624-1631
    • Tanizaki, J.1    Okamoto, I.2    Okamoto, K.3
  • 5
    • 84908205686 scopus 로고    scopus 로고
    • Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer
    • (abstract)
    • S.H. Ou, D.W. Kim, and D.R. Camidge Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer J Thorac Oncol 8 suppl 2 2013 S295 (abstract)
    • (2013) J Thorac Oncol , vol.8 , pp. 295
    • Ou, S.H.1    Kim, D.W.2    Camidge, D.R.3
  • 6
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib vs chemotherapy in advanced ALK-positive lung cancer
    • A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib vs chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
    • (2013) N Engl J Med , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.